BeiGene, Ltd., a clinical-stage biopharmaceutical company developing immuno-oncology drugs based in Beijing, China, is establishing its first cGMP biopharmaceutical manufacturing facility for commercial use at BioBAY in the Suzhou Industrial Park (SIP) in Suzhou, China.

BioBAY is a subsidiary of SIP, a science innovation hub in China housing more than 400 domestic and international biotech and biopharmaceutical companies for research, development, and manufacturing. BeiGene will also benefit from the local biotech talent pool with the establishment of a new site in BioBAY.

The new 9,000 square meter (96,875 square feet) cGMP manufacturing facility expands the company's production facilities and will supply materials for future clinical trials and subsequent commercial demand. The new manufacturing facility is expected to be completed by 2017.

BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 175 scientists and staff, BeiGene is advancing a pipeline consisting of oral small molecules and monoclonal antibodies for cancer.

Source: BeiGene